DexCom Raises 2026 Guidance as Revenue Grows 13% in Second Quarter
Continuous glucose monitoring company reports margin expansion and positive clinical trial results, lifting full-year outlook.
Strong Quarter Drives Guidance Increase
DexCom, Inc. (NASDAQ: DXCM) reported second quarter revenue of $1.308 billion, representing 13% year-over-year growth on a reported basis and 12% on an organic basis, according to the company's 8-K filing dated July 30, 2026. The San Diego-based continuous glucose monitoring manufacturer raised the midpoint of its fiscal year 2026 revenue guidance to a range of $5.18 billion to $5.25 billion, representing approximately 11-13% growth.
The company demonstrated geographic strength across both domestic and international markets. U.S. revenue grew 11% year-over-year, while international revenue expanded 19% on a reported basis and 16% organically (8-K filing, 2026-07-30). The ~$31 billion market cap company closed at $83.45 ahead of the earnings release.
Margin Expansion Highlights Operational Progress
Operating performance showed significant improvement compared to the prior year period. GAAP operating income reached $318.3 million, or 24.3% of revenue, marking a 590 basis point increase versus the second quarter of 2025 (8-K filing, 2026-07-30). Non-GAAP operating income totaled $328.3 million, or 25.1% of reported revenue, matching the same 590 basis point year-over-year expansion.
Gross margins also expanded substantially. GAAP gross profit of $830.0 million represented 63.4% of revenue, up from 59.5% in the year-ago quarter. Non-GAAP gross profit margin reached 64.1%, compared to 60.1% in Q2 2025 (8-K filing, 2026-07-30).
The company raised its full-year margin guidance, now expecting non-GAAP gross profit margin of approximately 64%, non-GAAP operating margin of 23.5-24%, and adjusted EBITDA margin of 31.5-32%.
Clinical and Product Developments
DexCom announced positive results from its CONNECT randomized controlled trial during the quarter. The study demonstrated that Dexcom CGM use among people with type 2 diabetes not using insulin "resulted in clinically meaningful and statistically significant improvements in glucose control compared to routine care" (8-K filing, 2026-07-30).
The company also initiated the launch of a redesigned Stelo app experience, incorporating AI-driven insights and enhanced food logging capabilities for consumers. These developments were highlighted at the company's 2026 Investor Day, where management presented market opportunities and a new long-term financial outlook through 2030.
"This quarter's performance and the successful outcomes from our CONNECT trial reinforce our confidence in the path ahead and position us well to deliver on our long-range plan," said Jake Leach, DexCom's president and CEO (8-K filing, 2026-07-30).
Financial Position and Earnings
DexCom reported GAAP net income of $249.1 million, or $0.64 per diluted share, compared to $179.8 million, or $0.45 per share, in Q2 2025. Non-GAAP net income reached $269.1 million, or $0.70 per diluted share, versus $192.8 million, or $0.48 per share, in the prior year period (8-K filing, 2026-07-30).
The company held $1.95 billion in cash, cash equivalents and marketable securities as of June 30, 2026, with its revolving credit facility remaining undrawn.
MarginX data shows recent insider selling activity, with SAYER KEVIN R selling 26,756 shares on two separate occasions and Brown Michael Jon selling 1,700 shares. The Federal Reserve has rate decisions scheduled for September 16 and October 28, 2026.
This article was generated by MarginX from the 8-K filing on 2026-07-30. It is not investment advice.